Poly Medicure Share Price Target 2027: What Earnings Say About Rs 1,725 and Rs 2,093

Investors weighing a Poly Medicure target price for 2027 should start with where the stock sits today. At Rs 1,646.80 on 5 November 2026, it is 21.4% below its 52-week high of Rs 2,094.30 and 39.3% above its 52-week low of Rs 1,182.00. That range spans 77% from low to high, so the entry point matters as much as the Poly Medicure price forecast itself.

This article builds the Poly Medicure share price target from reported numbers only: five years of annual results, the last five quarters, the latest shareholding pattern and current valuation ratios from company filings and exchange data. Each scenario states its assumptions, so you can trace how the base case, the bull case and the downside risk level were reached and test them against your own view.

Click Here – Get Free Investment Predictions

Poly Medicure Stock Analysis: Company Overview and Key Stats

Poly Medicure (NSE: POLYMED) has a market capitalisation of Rs 16,093 crore. In FY26 it reported revenue of Rs 1,995 crore and net profit of Rs 320.73 crore. The table collects the figures the Poly Medicure share price target is built on.

Metric	Value
Company	Poly Medicure
NSE Ticker	POLYMED
CMP (5 November 2026)	Rs 1,646.80
52-Week High	Rs 2,094.30
52-Week Low	Rs 1,182.00
Market Cap	Rs 16,093 crore
PE Ratio (TTM)	51.43
Industry PE	62.46
Price to Book	5.18
Return on Equity	10.37%
Debt to Equity	0.11
EPS (TTM)	Rs 30.87
Dividend Yield	0.22%
12-Month Base Target	Rs 1,725
Bull Case	Rs 2,093
Downside Risk Level (not a target)	Rs 1,270

Why Is Poly Medicure Share Price Target Set at Rs 1,725 for 2027?

The arithmetic is short. Trailing EPS of Rs 30.87 grown for one year gives a forward EPS estimate of Rs 33.54, and multiplying it by the unchanged PE of 51.43 gives the Rs 1,725 base-case Poly Medicure stock target. The bull case adds faster earnings growth and a higher multiple, while the downside risk level assumes flat earnings and a lower multiple.

Earnings Growth Behind the Poly Medicure Target Price: Five Years of Results

Poly Medicure grew revenue from Rs 960.97 crore in FY22 to Rs 1,995 crore in FY26, a compound annual growth rate of 20.0%. Net profit grew faster, from Rs 146.51 crore to Rs 320.73 crore (21.6% a year), which shows margin gains did part of the work and not just higher sales.

Financial Year	Revenue (Rs Cr)	Net Profit (Rs Cr)	EPS (Rs)	Dividend per Share (Rs)
FY22	960.97	146.51	15.27	2.50
FY23	1,151.42	179.28	18.67	3.00
FY24	1,434.54	258.26	26.90	3.00
FY25	1,758.96	338.56	34.11	3.50
FY26	1,995.34	320.73	31.75	3.50

FY26 revenue growth was 13.4%, slower than the four-year average of 20.0%, and net profit moved down 5.3%. EPS rose from Rs 26.90 in FY24 to Rs 31.75 in FY26. The FY27 outlook depends on whether that EPS estimate keeps compounding.

Margins and the Latest Quarter

Poly Medicure converted 16.1% of FY26 revenue into net profit, against 19.2% in FY25, within a five-year range of 15.2% to 19.2%. EBITDA margin was 28.1% in FY26 versus 31.1% in FY25.

In the June 2026 quarter, revenue was Rs 558.79 crore, up 25.5% from the same quarter a year earlier, while net profit of Rs 85.27 crore was down 8.4%. EBITDA came in at Rs 158.50 crore, up 7.2% year on year. The next quarterly result is the first test of whether the earnings assumption holds.

Balance Sheet and Cash Flow

Debt to equity stands at 0.11, and shareholders' equity grew from Rs 1,087 crore in FY22 to Rs 3,149 crore in FY26. Operating cash flow in FY26 was Rs 246.37 crore against capital expenditure of Rs 308.39 crore, leaving negative free cash flow of Rs 62.02 crore. In FY25 free cash flow was negative at Rs 97.98 crore.

Valuation Check for the Poly Medicure Stock Target: PE, Price to Book and ROE

At a PE of 51.43 against an industry PE of 62.46, Poly Medicure trades at a discount to its industry. Price to book is 5.18 on a book value of Rs 306.45 per share, and return on equity is 10.37%. A PE of 51.43 equals an earnings yield of 1.9%, and the FY26 dividend of Rs 3.50 per share gives a yield of 0.22%.

Shareholding Pattern and Institutional Holding

Promoters held 62.42% of Poly Medicure in September 2026, and promoter holding has stayed near 62.42% since September 2025. Foreign institutional investors (FII) held 5.35% and domestic institutions (DII) held 15.90%, which puts total institutional holding at 21.25%. FII holding fell from 9.77% in September 2025 to 5.35% in September 2026. Public shareholders own the remaining 16.33%. A meaningful institutional holding adds a layer of research coverage and trading depth.

Poly Medicure Share Price Targets for the Short Term and 12 Months

Short Term Poly Medicure Stock Target Levels: Technical Setup

At Rs 1,646.80 on 5 November 2026, Poly Medicure trades above its 50-day simple moving average of Rs 1,636.29 and below its 200-day exponential moving average of Rs 1,655.00. The 14-day RSI reads 57.6, which is neutral territory, and the MACD line sits above its signal line. The nearest resistance level is Rs 1,655.00 (200-day exponential moving average) and the nearest support is Rs 1,636.29 (50-day simple moving average). A sustained move above Rs 1,655.00 would improve the short-term setup, while a close below Rs 1,636.29 would shift attention to the next support.

12 Month Poly Medicure Target Price for 2027

The 12-month target of Rs 1,725 means a move of 4.7% up from Rs 1,646.80 over the next 12 months. It would still leave the stock 17.6% below its 52-week high of Rs 2,094.30. The upside in the base case is thin, so the thesis here leans on the bull case and on patience. Anyone checking the Poly Medicure share price target against their own view should focus on two inputs: the EPS estimate and the PE multiple.

How EPS Growth and PE Multiple Change the Poly Medicure Target Price

EPS Growth	PE 41.14	PE 51.43	PE 59.14
0.0% (EPS Rs 30.87)	Rs 1,270	Rs 1,588	Rs 1,826
8.6% (EPS Rs 33.54)	Rs 1,380	Rs 1,725	Rs 1,984
14.6% (EPS Rs 35.39)	Rs 1,456	Rs 1,820	Rs 2,093

Each cell multiplies the forward EPS estimate by the PE shown. Reading across a row shows what a de-rating or re-rating does to the Poly Medicure price forecast, and reading down a column shows what earnings growth is worth at a fixed multiple.

Bull Case and Downside Risk for Poly Medicure Stock Target in 2027

Bull Case Rs 2,093

The bull case Poly Medicure price target needs EPS growth of 14.6%, which lifts forward EPS to Rs 35.39, and a PE multiple that rises 15% to 59.14. That gives Rs 2,093, 27.1% above the current price and below the 52-week high of Rs 2,094.30.

Downside Risk Level Rs 1,270

The downside risk level is not a target. It assumes EPS stays flat at Rs 30.87 and the PE falls 20% to 41.14. That gives Rs 1,270, 22.9% below the current price and above the 52-week low of Rs 1,182.00.

Scenario	EPS Growth	PE Multiple	Price (Rs)	Change vs CMP
Bull Case	14.6%	59.14	Rs 2,093	+27.1%
Base Case	8.6%	51.43	Rs 1,725	+4.7%
Downside Risk	0.0%	41.14	Rs 1,270	-22.9%

Key Risks to the Poly Medicure Target Price for 2027

Growth Slowdown Risk for the Poly Medicure Price Target

Revenue in the June 2026 quarter was up 25.5% year on year, and FY26 revenue growth was 13.4%. If growth slows from here, the EPS estimate behind the Poly Medicure stock target will need revising.

Liquidity and Size Risk

Poly Medicure has a market capitalisation of Rs 16,093 crore. Institutional holding is 21.25%, and promoters hold 62.42%. Stocks of this size are usually liquid, though exits can take longer than entries when the market is falling.

Valuation and Margin Risk

Net margin was 16.1% in FY26, and a squeeze from higher costs or weaker pricing would hit earnings first. At a PE of 51.43 versus an industry PE of 62.46, a de-rating toward the downside-risk PE of 41.14 would cut the price even if earnings hold.

Market and Technical Risk

Technical indicators add short-term risk: the 14-day RSI is 57.6 and the MACD sits above its signal line. A broad fall in the Nifty 50 or the Sensex can override company fundamentals for weeks at a time.

How to Invest in Poly Medicure

Start with the live price and volume. Any Poly Medicure share price target is only as current as the data behind it, and the data here is as of 5 November 2026, so refresh the Rs 1,646.80 price before acting on any level.

Next, review the fundamentals yourself. The Univest Screener lets you check Poly Medicure's PE, ROE, debt and shareholding in one place.

Check Poly Medicure fundamentals on the Univest Screener

Then compare the three Poly Medicure target price scenarios with your own view. If you expect EPS growth below 8.6%, the base case is too optimistic for you; if you expect more, the bull case deserves weight.

Decide your position size and exit levels before you buy. The support and resistance levels above can serve as reference points, but they are not recommendations.

Finally, place the order through a SEBI-registered broker or the Univest app, and review the position after each quarterly result. Consult a SEBI-registered advisor if you are unsure.

Download the Univest iOS App or Univest Android App to track Poly Medicure live price and get daily stock recommendations.

Conclusion

The Poly Medicure share price target for 2027 is Rs 1,725 in the base case, with Rs 2,093 as the bull case. The support for that view is arithmetic you can check: EPS grew 8.6% a year over FY24 to FY26, and the stock trades at a PE of 51.43. The risks are equally concrete, including a valuation that can de-rate even when earnings hold and a downside scenario that cuts the price 23% if earnings stall. Use these numbers as a framework, check them against the latest filings, and size any position to your own risk appetite.

FAQs on Poly Medicure Share Price Target 2027

What is the Poly Medicure share price target for 2027?

Ans. The base-case Poly Medicure share price target for 2027 is Rs 1,725, which is 4.7% above the price of Rs 1,646.80 on 5 November 2026. The bull case is Rs 2,093 and the downside risk level, which is not a target, is Rs 1,270. All three come from one method: forward EPS multiplied by a PE multiple, using only reported results. They are model estimates and not guaranteed outcomes, and the next quarterly result is the first check on the EPS assumption.

What is the Poly Medicure share price today?

Ans. As of 5 November 2026, 11:30 AM IST, Poly Medicure (NSE: POLYMED) trades at Rs 1,646.80, up 3.78% on the day. That is 21.4% below the 52-week high of Rs 2,094.30 and 39.3% above the 52-week low of Rs 1,182.00. The market capitalisation of Rs 16,093 crore places it among mid-cap stocks. Prices change through the trading session, so check the live quote before acting on any level in this article.

Is Poly Medicure a buy or sell at the current price?

Ans. The data points both ways. On the positive side, EPS has grown 8.6% a year over FY24 to FY26 and the base case implies 4.7% upside; on the cautious side, the valuation can de-rate even when earnings hold, and the downside risk level of Rs 1,270 is 23% below the current price. Whether Poly Medicure fits your portfolio depends on your time horizon, position size and risk appetite. Consult a SEBI-registered advisor before investing, as this article is not investment advice.

What are the bull case target and downside risk level for Poly Medicure shares?

Ans. The bull case in the Poly Medicure share price target for 2027 is Rs 2,093, which assumes 14.6% EPS growth and a PE of 59.14, a 15% re-rating from today's multiple. That is 27.1% above the current price and below the 52-week high of Rs 2,094.30. The downside risk level is Rs 1,270, which assumes flat EPS and a PE of 41.14, 20% lower than today. It sits 22.9% below the current price and above the 52-week low of Rs 1,182.00, and it marks a risk to watch, not a target.

What are the main risks to the Poly Medicure price target?

Ans. Four risks matter most for the Poly Medicure share price target: slower revenue or profit growth, a PE de-rating, thin liquidity or size risk, and weakness in the broader market. With a market capitalisation of Rs 16,093 crore, the stock is usually liquid, though exits can take longer than entries in a falling market. A fall to the downside-risk PE of 41.14 would cut the price even if earnings hold.

What is the PE ratio of Poly Medicure and how does it compare with the industry?

Ans. The PE ratio of Poly Medicure is 51.43, against an industry PE of 62.46, which is a discount to the industry. Price to book is 5.18 and return on equity is 10.37%, and the PE equals an earnings yield of 1.9%. The base case holds the PE unchanged, so the Poly Medicure share price target moves only with earnings, while the bull and downside scenarios change the multiple by +15% and -20%.

Who owns Poly Medicure, and what is the promoter holding?

Ans. Promoters held 62.42% of Poly Medicure in September 2026. FII held 5.35%, DII held 15.90% and the public held 16.33%. Together the two institutional groups hold 21.25%. Shareholding is filed every quarter, so it is worth rechecking after each result.

What were Poly Medicure's latest quarterly results?

Ans. In the June 2026 quarter, Poly Medicure reported revenue of Rs 558.79 crore (up 25.5% year on year) and net profit of Rs 85.27 crore (down 8.4%). For comparison, FY26 full-year revenue growth was 13.4% and net profit moved down 5.3%. Each new quarter either supports or weakens the EPS growth of 8.6% assumed in the base case.